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E D I T O R I A L
Management of systemic sclerosis-associated interstitial lung 
disease in the current era
Interstitial lung disease (ILD) is a group of diseases describing thick-
ening of the interstitium surrounding pulmonary alveolar walls due 
to underlying inflammation. ILD is often associated with connective 
tissue diseases. Among connective tissue disease-related ILDs, 80% 
of systemic sclerosis (SSc) patients develop ILD1 with associated 
morbidity and mortality,2 although a large proportion may not de-
velop clinically significant disease. Screening, early diagnosis and 
treatment of SSc-associated ILD (SSc-ILD) is important as up to 33% 
of SSc-related deaths are attributed to ILD3 and initiating treatment 
early in the course of the disease has been shown to slow disease 
progression.4,5 This article summarizes the risk factors for SSc-ILD 
and best practices for diagnosis and treatment of SSc-ILD.
1  | RISK FAC TORS AND SCREENING
The goal of treatment in SSc-ILD is prevention of progression where 
progression is defined as new or worsening symptoms, increase in 
the extent of pulmonary fibrosis on high-resolution computed to-
mography (HRCT) and/or by a decline in pulmonary function tests 
(PFTs).6,7 This highlights the need for identifying patients at risk of 
disease progression before worsening occurs. The risk factors for 
progressive ILD are shown in Table 1. Although no absolute risk fac-
tors have been identified, these risk factors have been reported to 
be associated with progressive ILD in patients with SSc.
The risk of developing ILD is greatest early in the course of the 
disease and the most rapid decline in lung function (forced vital ca-
pacity [FVC]) occurs within the initial 3-5 years of disease onset.5 
In addition, the extent of lung involvement on HRCT at baseline 
combined with reduced or declining FVC and diffusing capacity of 
the lung for carbon monoxide (DLCO) is predictive of mortality.6,8-10 
Currently, the diagnosis of SSc-ILD is based on characteristic find-
ings of increase reticulations with or without ground glass opacity on 
HRCT of the chest, irrespective of PFT results. Therefore, it is rec-
ommended that all patients with SSc receive HRCT at baseline.11,12 
Additionally, all patients should be evaluated for evidence of cardiac 
involvement including assessment for pulmonary hypertension at 
the initial visit.13
Due to concern for radiation exposure with repeated HRCT, 
evaluation of lung function via spirometry and DLCO is recom-
mended every 4-6 months in the first 3-5 years of the disease onset 
as this has been shown to provide valuable information about dis-
ease trajectory.6,14,15
2  | TRE ATMENT
The concepts for management of autoimmune ILD, including SSc-
ILD, is shown in Figure 1. Not every patient with SSc-ILD requires 
treatment. Since early SSc-ILD is driven by immune activation and 
inflammation, the current approach involves the use of immunosup-
pressive therapy with the goal of initiation early in the disease to pre-
vent advanced fibrotic disease.16 Our group has recently published 
single-center recommendations on the management of SSc-ILD.17 
One strategy is to stratify patients by their lung disease severity 
(subclinical [defined as minimal ILD on HRCT, normal or near nor-
mal FVC and DLCO with no symptoms attributable to ILD] vs clinical 
ILD). For those with subclinical ILD, one may initiate therapy for ILD, 
especially with high-risk features or monitor closely for progressing 
symptoms, PFTs, and with repeat HRCT if necessary.17 Current prac-
tice involves treating patients on a case by case basis and only after 
careful review of risks vs benefits, as there is significant toxicity as-
sociated with some of the available medications.
The treatment for SSc-ILD has included the use of immunosup-
pressive therapies, in particular cyclophosphamide (CYC) and myco-
phenolate mofetil (MMF). MMF is largely used in North America and 
the UK for the management of SSc-ILD and it is generally given as 
3000 mg/d in divided doses. This is based on the Scleroderma Lung 
Study II which showed that treatment with MMF offers comparable 
efficacy as oral CYC and has a better safety profile.18
Recent data from a Phase 3 trial showed that the treatment of 
early ILD (mean FVC% of 82% with mild ILD on HRCT) in high-risk 
populations (early diffuse cutaneous SSc and elevated C-reactive 
protein [CRP] with 50% having positive anti-SCL-70 antibodies) with 
tocilizumab led to stabilization of FVC% vs a decline of 6.5% in the 
placebo group at 48 weeks.19 Similarly, an open-label trial of patients 
with early diffuse cutaneous SSc and positive anti-SCL-70 found 
improvement in FVC% at 24 weeks with the use of two courses of 
rituximab (1000 mg × 2 doses) vs monthly pulse CYC.20 We offer 
treatment to patients with subclinical ILD and elevated CRP and/or 
positive anti-SCL-70.
Other therapy includes autologous hematopoietic stem cell 
transplantation (HSCT). Several trials have shown that HSCT fol-
lowing immunosuppressives has a beneficial effect in some patients 
with diffuse cutaneous SSc with multi-organ involvement.21 The ap-
propriate patient has early disease with progressive ILD and is not 
responding to immunosuppressive therapy. The goal is to target ag-
gressive and reversible disease.
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As shown in Figure 1, a clinician may consider anti-fibrotic ther-
apies in patients with progressive ILD or those intolerant of immu-
no-modulatory therapy (eg, due to recurrent infections). The SENSCIS 
trial, a large Phase 3 trial, demonstrated a smaller decline in FVC with 
the addition of nintedanib (an intracellular multiple tyrosine kinase 
inhibitor) to background MMF or no therapy vs placebo.22 Based 
on published data, sequential combination therapy could be consid-
ered for patients with high risk of progression (not addressed in the 
SENSCIS trail), where progression has occurred under monotherapy, 
or contraindication to the immunosuppressive therapy.
In addition to the above, comorbid conditions including infections 
and gastrointestinal disease/gastro-esophageal reflux disease (GERD) 
leading to chronic aspiration should be considered in patient with 
SSc-ILD. In addition to treatment of GERD, appropriate immunization, 
supplemental oxygen to keep saturations above 88%, and education 
on tobacco cessation should be part of every patient's ongoing care. 
Lastly, pulmonary rehabilitation may be effective for some patients.23
3  | CONCLUSION/SUMMARY
Aside from autologous hematopoietic stem cell transplant, there 
is limited evidence to support a mortality benefit among SSc-ILD 
treatments and the benefits of all treatment strategies including 
combination therapies will need to be weighed against their side 
effects. Current management includes immunosuppressive ther-
apy in those with subclinical ILD with high-risk features or those 
with clinical ILD. Anti-fibrotics should be considered in those with 
progressive ILD despite being on immunosuppressive therapy or if 
there is contraindication to immunosuppressive therapy. The ongo-
ing trial Scleroderma Lung Study III is assessing if upfront combi-
nation of MMF and pirfenidone (anti-fibrotic) is more efficacious 
than MMF alone in early SSc-ILD (https ://medic ine.umich.edu/
sites/ defau lt/files/ conte nt/downl oads/Scler oderm aLung Studi es-
Augus t2019-Final.pdf). Future research in SSc-ILD should aim at 
developing tools to identify patients at risk of progressive SSc-ILD 
and assess appropriate timing and treatment sequences in patients 
with SSc.
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Anti-nucleolar Ab (representing AntiTh/To, U3RNP)
C-reactive protein/interleukin-6
Chemokine (C-C motif) ligand (CCL-18)
Krebs von den Lungen protein (KL6)b
Surfactant protein D (SP-D)b
Abbreviations: Anti-SCL 70, anti-scleroderma-70 antibody; SSc, 
systemic sclerosis.
aRecently reviewed in Khanna et al.1 
bCCL-18, KL6 and SP-D are serum markers for endothelial injury. 
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